Abstract
The aim of the study was to determine whether an elevated IgA level at the time of the diagnosis of IgA nephropathy has an effect on the severity of kidney biopsy findings and long-term outcomes in children. We retrospectively studied 89 children with IgA nephropathy who were stratified into Group 1- elevated serum IgA and Group 2 – normal serum IgA at baseline. The level of IgA, proteinuria, hematuria, glomerular filtration rate (GFR) and hypertension (HTN) were compared at baseline and after the end of the follow-up period of 4.0 ± 3.1 years. Kidney biopsy findings were evaluated using the Oxford classification. The evaluation of treatment included immunosuppressive therapy and renoprotection with angiotensin converting-enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), or no treatment. The elevated serum IgA was found in 46 (52 %) patients and normal serum IgA level was found in 43 (48 %) patients. No differences were found between the two groups regarding the mean age of patients, proteinuria, and the number of patients with reduced GFR or HTN at baseline. In kidney biopsy, mesangial proliferation and segmental sclerosis were significantly more common in Group 1 compared with Group 2 (p < 0.05). Immunosuppressive therapy was used in 67 % children in Group 1 and 75 % children in Group 2. The Kaplan-Meier survival curves for renal function (with normal GFR) and persistent proteinuria did not differ significantly depending on the serum IgA level at baseline. We conclude that in IgA nephropathy the elevated serum IgA at baseline may be associated with mesangial proliferation and segmental sclerosis contribute to glomerulosclerosis, but has no effect on the presence of proteinuria or on the worsening of kidney function during several years of disease course.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bulut IK, Mir S, Sozeri B, Bulut MO, Sen S, Dincel N (2012) Outcome results in children with IgA nephropathy: a single center experience. Int J Nephrol Renovasc Dis 5:23–28
Coppo R, D’Amico G (2005) Factors predicting progression of IgA nephropathies. J Nephrol 18:503–512
Emancipator SN, Gallo GR, Lamm ME (1995) IgA nephropathy: perspective on pathogenesis and classification. Clin Nephrol 24:161–179
Galla JH (1995) Perspectives in clinical nephropathy. Kidney Int 47:377–387
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2005) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents, revised version May 2005. U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda
Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, Julian BA, Wyatt RJ, Mestecky J (2005) IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 67:504–513
Pozzi C, Andruli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, Vogt B, De Cristofaro V, Allegri L, Cirami L, Procaccini AD, Locatelli F (2010) Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21:1783–1790
Roberts ISD, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D’Agati V, D’Amigo G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jenette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PKT, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations and reproducibility. Kidney Int 76:546–556
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637
Silva FG, Hogg RJ (1989) IgA nephropathy. In: Tisher CC, Brenner BM (eds) Renal pathology with clinical and functional correlations. Lippincott, Philadelphia, pp 434–493
Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J (2009) Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119:1668–1677
Tanaka M, Seki G, Someya T, Nagata M, Fujita T (2011) Aberrantly glycosylated IgA1 as a factor in a pathogenesis of IgA nephropathy. Clin Dev Immunol 2011:470803. doi:10.1155/2011/470803
Tomino Y, Suzuki S, Imai H, Saito T, Kawamura T, Yorioka N, Harada T, Yosumoto Y, Kida H, Kabayashi Y, Endoh M, Sato H, Saito K (2000) Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. J Clin Lab Anal 14:220–223
Van der Boog P, Van Kooten C, De Fijter J (2005) Role of macromolecular IgA in IgA nephropathy. Kidney Int 67:813–821
Yoshikava N, Tanaka R, Iijima K (2001) Pathophysiology and treatment of IgA nephropathy in children. Pediatr Nephrol 16:446–457
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mizerska-Wasiak, M. et al. (2015). Increased Serum IgA in Children with IgA Nephropathy, Severity of Kidney Biopsy Findings and Long-Term Outcomes. In: Pokorski, M. (eds) Ventilatory Disorders. Advances in Experimental Medicine and Biology(), vol 873. Springer, Cham. https://doi.org/10.1007/5584_2015_160
Download citation
DOI: https://doi.org/10.1007/5584_2015_160
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-20193-1
Online ISBN: 978-3-319-20194-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)